On August 2, 2023 Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, reported that it is going to release results from two clinical studies at the 2023 European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress (Press release, Ascentage Pharma, AUG 2, 2023, View Source;ascentage-pharma-to-present-results-from-two-clinical-studies-including-one-oral-presentation-at-2023-esmo-congress-301892332.html [SID1234633672]). These presentations include a Mini Oral featuring the latest data from a study of pelcitoclax (APG-1252), a Bcl-2/BcL-xL dual-targeted inhibitor, combined with osimertinib in patients with EGFR-mutant non-small cell lung cancer (NSCLC); and a Poster on a study evaluating olverembatinib (HQP1351), the first and only China-approved third-generation BCR-ABL inhibitor, in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As one of the most authoritative and influential congresses in oncology globally, the ESMO (Free ESMO Whitepaper) Congress showcases the latest results from some of the most cutting-edge research from around the world. This year, the ESMO (Free ESMO Whitepaper) Congress will take place on October 20 to October 24, local time, in Madrid, Spain.

"We are pleased that results from the study of pelcitoclax combined with osimertinib in patients with NSCLC and that from the study evaluating olverembatinib in patients with succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST) have been selected for presentations at the 2023 ESMO (Free ESMO Whitepaper) Congress," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "These presentations highlight Ascentage Pharma’s robust capabilities in clinical development and global innovation, as well as our strong potential in solid tumors. Remaining steadfastly committed to our global innovation roadmap, we will expeditiously advance the global clinical development of our lead drug candidates with the hope to bring benefit to patients in China and around the world as soon as possible."

These two clinical studies to be presented at the ESMO (Free ESMO Whitepaper) Congress this year are as follows:

Pelcitoclax

Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

Format: Mini Oral
Abstract#: 5586
Category: NSCLC, Locally Advanced
First Author: Yuxiang Ma, MD, Sun Yat-sen University Cancer Center
Olverembatinib

Antitumor activity of olverembatinib (HQP1351) in patients (pts) with TKI-resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST)

Format: Poster
Abstract#: 5746
Category: Sarcoma
First Author: Haibo Qiu, MD, PhD, Sun Yat-sen University Cancer Center
*Pelcitoclax is an investigational drug that has not been approved in any country and region.

*Olverembatinib is an investigational drug that has not been approved for any indication outside the Chinese mainland. This drug is jointly commercialized in China by Ascentage Pharma and Innovent Biologics.